Soluble coxsackievirus B3 3C protease inhibitor prevents cardiomyopathy in an experimental chronic myocarditis murine model. 2015

Byung-Kwan Lim, and Soo-Hyeon Yun, and Eun-Seon Ju, and Bo-Kyoung Kim, and You-Jung Lee, and Dong-Kyeom Yoo, and Young-Chul Kim, and Eun-Seok Jeon
Department of Biomedical Science, Jungwon University, Goesan-gun, South Korea.

BACKGROUND Coxsackievirus B3 (CVB3) is a common cause of myocarditis and dilated cardiomyopathy. CVB3 3C protease (3CP) cleaves the viral polyprotein during replication. We tested whether a water soluble 3CP inhibitor (3CPI) had antiviral effects in a chronic myocarditis model. METHODS Chronic myocarditis was established using DBA/2 strain mice. Starting on post-infection (p.i) day 3, CVB3-infected mice (n=41) were treated with 3CPI by daily intraperitoneal (i.p.) injection at a concentration of 50 μM (1.7 mg/kg/day) per day for 3 consecutive days. Additional mice (n=49) were injected with PBS as a control. RESULTS The 5-week survival rate was significantly higher with 3CPI treatment (82.3% versus 47.9%; P<0.05). Organ virus titers at day 3 and 7 and myocardial damage were significantly lower in 3CPI-treated mice. Echocardiography at day 31 indicated strong protection of heart function by 3CPI (FS, 51.2±1.5 versus 26.1±1.5%; P<0.001). Hemodynamic measurements indicated that 3CPI treatment markedly reduced CVB3-induced LV dysfunction on day 31 (dP/dTmax, 5302±352 versus 4103±408 mmHg/s, P<0.05; dP/dTmin, -3798±212 versus -2814±206 mmHg/s, P<0.01). CONCLUSIONS Water soluble 3CPI was delivered through i.p. injection after CVB3 infection. This agent preserved heart function and decreased organ viral titers and myocardial damage. Soluble 3CPI may be beneficial in the treatment of cardiomyopathy associated with enterovirus infection.

UI MeSH Term Description Entries
D008297 Male Males
D008811 Mice, Inbred DBA An inbred strain of mouse. Specific substrains are used in a variety of areas of BIOMEDICAL RESEARCH such as DBA/1J, which is used as a model for RHEUMATOID ARTHRITIS. Mice, DBA,Mouse, DBA,Mouse, Inbred DBA,DBA Mice,DBA Mice, Inbred,DBA Mouse,DBA Mouse, Inbred,Inbred DBA Mice,Inbred DBA Mouse
D009202 Cardiomyopathies A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS). Myocardial Disease,Myocardial Diseases,Myocardial Diseases, Primary,Myocardial Diseases, Secondary,Myocardiopathies,Primary Myocardial Disease,Cardiomyopathies, Primary,Cardiomyopathies, Secondary,Primary Myocardial Diseases,Secondary Myocardial Diseases,Cardiomyopathy,Cardiomyopathy, Primary,Cardiomyopathy, Secondary,Disease, Myocardial,Disease, Primary Myocardial,Disease, Secondary Myocardial,Diseases, Myocardial,Diseases, Primary Myocardial,Diseases, Secondary Myocardial,Myocardial Disease, Primary,Myocardial Disease, Secondary,Myocardiopathy,Primary Cardiomyopathies,Primary Cardiomyopathy,Secondary Cardiomyopathies,Secondary Cardiomyopathy,Secondary Myocardial Disease
D011480 Protease Inhibitors Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). Antiprotease,Endopeptidase Inhibitor,Endopeptidase Inhibitors,Peptidase Inhibitor,Peptidase Inhibitors,Peptide Hydrolase Inhibitor,Peptide Hydrolase Inhibitors,Peptide Peptidohydrolase Inhibitor,Peptide Peptidohydrolase Inhibitors,Protease Antagonist,Protease Antagonists,Antiproteases,Protease Inhibitor,Antagonist, Protease,Antagonists, Protease,Hydrolase Inhibitor, Peptide,Hydrolase Inhibitors, Peptide,Inhibitor, Endopeptidase,Inhibitor, Peptidase,Inhibitor, Peptide Hydrolase,Inhibitor, Peptide Peptidohydrolase,Inhibitor, Protease,Inhibitors, Endopeptidase,Inhibitors, Peptidase,Inhibitors, Peptide Hydrolase,Inhibitors, Peptide Peptidohydrolase,Inhibitors, Protease,Peptidohydrolase Inhibitor, Peptide,Peptidohydrolase Inhibitors, Peptide
D003384 Coxsackievirus Infections A heterogeneous group of infections produced by coxsackieviruses, including HERPANGINA, aseptic meningitis (MENINGITIS, ASEPTIC), a common-cold-like syndrome, a non-paralytic poliomyelitis-like syndrome, epidemic pleurodynia (PLEURODYNIA, EPIDEMIC) and a serious MYOCARDITIS. Coxsackie Virus Infections,Infections, Coxsackie Virus,Infections, Coxsackievirus,Coxsackie Virus Infection,Coxsackievirus Infection
D003546 Cysteine Endopeptidases ENDOPEPTIDASES which have a cysteine involved in the catalytic process. This group of enzymes is inactivated by CYSTEINE PROTEINASE INHIBITORS such as CYSTATINS and SULFHYDRYL REAGENTS.
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D006321 Heart The hollow, muscular organ that maintains the circulation of the blood. Hearts
D006334 Heart Function Tests Examinations used to diagnose and treat heart conditions. Cardiac Function Tests,Cardiac Function Test,Function Test, Cardiac,Function Test, Heart,Function Tests, Cardiac,Function Tests, Heart,Heart Function Test,Test, Cardiac Function,Test, Heart Function,Tests, Cardiac Function,Tests, Heart Function
D000086042 3C Viral Proteases A class of cysteine proteases which play an essential role in VIRUS REPLICATION. They cleave precursor viral POLYPROTEINS to produce functional proteins and enzymes. In addition, they cleave certain host cell proteins such as EUKARYOTIC INITIATION FACTOR-4G. 3C Proteases,3C Proteinases,3C-like Viral Proteases,3Cpro Proteinases,Proteases, 3C,Proteases, 3C-like Viral,Proteinases, 3C,Viral Proteases, 3C-like

Related Publications

Byung-Kwan Lim, and Soo-Hyeon Yun, and Eun-Seon Ju, and Bo-Kyoung Kim, and You-Jung Lee, and Dong-Kyeom Yoo, and Young-Chul Kim, and Eun-Seok Jeon
December 2002, International journal of cardiology,
Byung-Kwan Lim, and Soo-Hyeon Yun, and Eun-Seon Ju, and Bo-Kyoung Kim, and You-Jung Lee, and Dong-Kyeom Yoo, and Young-Chul Kim, and Eun-Seok Jeon
July 2015, FEBS letters,
Byung-Kwan Lim, and Soo-Hyeon Yun, and Eun-Seon Ju, and Bo-Kyoung Kim, and You-Jung Lee, and Dong-Kyeom Yoo, and Young-Chul Kim, and Eun-Seok Jeon
January 2017, PloS one,
Byung-Kwan Lim, and Soo-Hyeon Yun, and Eun-Seon Ju, and Bo-Kyoung Kim, and You-Jung Lee, and Dong-Kyeom Yoo, and Young-Chul Kim, and Eun-Seok Jeon
January 1992, Heart and vessels,
Byung-Kwan Lim, and Soo-Hyeon Yun, and Eun-Seon Ju, and Bo-Kyoung Kim, and You-Jung Lee, and Dong-Kyeom Yoo, and Young-Chul Kim, and Eun-Seok Jeon
November 2016, Journal of microbiology and biotechnology,
Byung-Kwan Lim, and Soo-Hyeon Yun, and Eun-Seon Ju, and Bo-Kyoung Kim, and You-Jung Lee, and Dong-Kyeom Yoo, and Young-Chul Kim, and Eun-Seok Jeon
September 1983, Infection and immunity,
Byung-Kwan Lim, and Soo-Hyeon Yun, and Eun-Seon Ju, and Bo-Kyoung Kim, and You-Jung Lee, and Dong-Kyeom Yoo, and Young-Chul Kim, and Eun-Seok Jeon
March 1996, Virus research,
Byung-Kwan Lim, and Soo-Hyeon Yun, and Eun-Seon Ju, and Bo-Kyoung Kim, and You-Jung Lee, and Dong-Kyeom Yoo, and Young-Chul Kim, and Eun-Seok Jeon
January 2003, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology,
Byung-Kwan Lim, and Soo-Hyeon Yun, and Eun-Seon Ju, and Bo-Kyoung Kim, and You-Jung Lee, and Dong-Kyeom Yoo, and Young-Chul Kim, and Eun-Seok Jeon
November 2019, Circulation. Heart failure,
Byung-Kwan Lim, and Soo-Hyeon Yun, and Eun-Seon Ju, and Bo-Kyoung Kim, and You-Jung Lee, and Dong-Kyeom Yoo, and Young-Chul Kim, and Eun-Seok Jeon
January 1999, Annals of the New York Academy of Sciences,
Copied contents to your clipboard!